Dr Patricia Camilla Gorecki

Company Overview: Kenvue Division, Essential Health, Oral Healthcare.

Global Medical Affairs and Strategy Lead, covering R&D, Medical Affairs, Scientific Engagement, for the global and North America business, key achievements being:

• Successful implementation of new ways of working by demonstrating need of, introducing and executing therapy area-specific global medical affairs strategy and tactical plan for 2025, aligned with business strategy and regional medical teams.
• Introduction of vendor support for medical affairs projects (including selection, due diligence, contracting, budget management).
• Developed high-performing teams by providing mentorship, guidance, and opportunities for professional growth.
• Enhanced cross-functional team collaboration through regular communication, goal setting, and performance evaluations.
• Managed budgets effectively to ensure optimal use of resources while maintaining financial stability.

Introduction of New Ways of Working related to external engagement and insights gathering:

• Global and US Key Opinion Leader identification, mapping and relationship building.
• Delivery of three global advisory boards in H1 2024 to gain key insights for development of business strategy (first advisory board setup in years).
• Introduction of insights gathering activities at conferences, including competitive conference reports.
• Partnership set-up with international organisations, e.g World Dental Federation (FDI), International Association for Dental Research (IADR) or American Dental Association (ADA).

Evidence Generation:

• Introduction of publication development in partnership with KOLs.
• Clinical Trial Director for Phase 3 and 4 company-sponsored, randomised clinical trials, Clinicaltrials.gov identifier: NCT06010758, NCT05756673, NCT05526586, NCT05645705.
• Clinical Strategy Lead for regulatory submissions to FDA (OMOR OTC Monograph Order Request).

Company Overview: Janssen Immunology, Dermatology.

Growth as a medical leader by moving to first regional role, key achievements being:

• Introduction and delivery of Medical Communications strategy and a core narrative for the EMEA region.
• Delivery of insights generation activities, including for pipeline assets in atopic dermatitis and psoriasis, to feed into global medical and R&D plans.
• Established relationships with external customers to gain insights into decision-making and brand strategy development.
• Evidence Generation: Study-responsible scientist for company-sponsored, Phase 3, randomised clinical trial (Clinicaltrials.gov identifier: NCT03998683), post-hoc data analyses of clinical trials and real-world database analyses with publications at scientific conferences and in medical journals.

Company Overview: Janssen UK Immunology, Rheumatology.

First medical head office role, key achievements include:

• Successful UK regulatory approval (NICE and SMC) and product pre-/launch in rheumatology.
• Provided scientific support during product launches, ensuring appropriate messaging and positioning within the market, enabling a successful launch.
• Evaluated competitor landscape through strategic analysis techniques, identifying opportunities for differentiation.
• Educated sales representatives on product benefits and safety profiles, enhancing their ability to effectively communicate with physicians.

Real World Evidence and Data Generation:

• Successful facilitation and set-up of two investigator-initiated studies with UK KOLs.
• Successful initiation of a regional (EMEA-wide) real-world evidence study.
• Enhanced patient outcomes by providing expert medical advice and guidance to healthcare professionals.
• Expansion of UK clinical trial programmes, by identifying new investigators for pipeline clinical trials and studies for new clinical indications of existing products.
• Delivery of first advisory board with Patient Advocacy Groups.
• Scrutinised promotional materials for medical accuracy and compliance with guidelines and regulations.
• Medical Education Manager in Rheumatology (in addition to Medical Advisor role): set-up and delivery of first virtual events and online education hub during COVID pandemic.

Company Overview: Janssen UK Immunology.

First industry role after moving from academia, focus on understanding industry interaction with healthcare system and how to support business strategy as a field-based employee; key achievements include:

• Initiation and set up of Phase IV observational study in dermatology with key UK KOL
• Delivery of Real-World Evidence publication using database analyses in dermatology (BADBIR)
• Support setting up new Phase 3 clinical trial programme in gastroenterology in collaboration with clinical operations team, including identifying the trial principal investigator and new trial sites
• Support of Medical Education activities (speaker briefings, presentation reviews, advisory boards)
• Served as the primary point of contact, fostering strong relationships between internal teams and external partners.
• Aided in the development of training materials, contributing to the ongoing education of team members and improved performance outcomes.

Previous clinical and academic appointment:

• Responsibilities included research grant applications, management and coordination of undergraduate examinations, participation in recruitment process of new departmental staff
• Patient management covering oral and maxillofacial surgery, oral medicine, oral immunology, head and neck oncology.

Previous clinical appointment:

• Completion of Oral Surgery Specialty Training (Specialist Registrar with National Training Number [NTN]) incl treatment of subjects with autoimmune and immune-mediated diseases and head/neck cancer (solid tumours, haematological malignancies)
• Clinical Trial Co-Investigator (Phase IV, Clinicaltrials.gov identifier NCT02777970), Clinical Trial Assistant (Phase II/III, Clinicaltrials.gov identifiers: NCT1145820, NCT01706588, NCT00942448)

Previous clinical appointment, managing and treating patients referred to oral and maxillofacial surgery department, including emergencies, oral surgery and head/neck malignancies.

Previous clinical appointment, conducting retrospective case-control study focussing on identifying marker for early detection of head/neck squamous cell carcinoma.